International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS)
- PMID: 20667058
- DOI: 10.1111/j.1524-4733.2010.00767.x
International development of the patient-reported outcome indices for multiple sclerosis (PRIMUS)
Abstract
Background: The Patient-Reported Indices for Multiple Sclerosis (PRIMUS) comprises a suite of three scales for assessing symptoms, activity limitations, and quality of life in multiple sclerosis (MS). It was developed in the UK and has been shown to have excellent psychometric properties. This study describes the adaptation of eight language versions for Canadian English, Canadian French, French, German, Italian, Spanish, Swedish, and US English.
Methods: The PRIMUS was translated using the dual-panel process. Cognitive debriefing interviews conducted with MS patients assessed face and content validity. Psychometric and scaling properties were assessed via a two-administration postal survey conducted in each country involving the PRIMUS, the Nottingham Health Profile (NHP), the Unidimensional Fatigue Impact Scale (U-FIS), and demographic questions.
Results: Cognitive debriefing interviews demonstrated the acceptability of the new language versions. Analysis of survey data showed that the new language versions of the three PRIMUS scales were unidimensional (as indicated by fit to the Rasch model) and that they had good internal consistency and reproducibility. PRIMUS scale scores correlated as expected with those on the NHP and the U-FIS. The scales in all countries were able to discriminate between groups of patients on the basis of their self-reported MS severity, general health, and employment status.
Conclusions: The PRIMUS was successfully adapted into eight new languages. Most of the tests showed the PRIMUS to have good unidimensionality and to have good internal consistency, reproducibility, and construct validity. The measure is now available for use in clinical studies and trials involving these countries and the UK. Further work is required to assess the measure's responsiveness.
© 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
Similar articles
-
International development of the Unidimensional Fatigue Impact Scale (U-FIS).Value Health. 2010 Jun-Jul;13(4):463-8. doi: 10.1111/j.1524-4733.2010.00706.x. Epub 2010 Mar 11. Value Health. 2010. PMID: 20230543
-
Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire.Health Qual Life Outcomes. 2007 Feb 2;5:7. doi: 10.1186/1477-7525-5-7. Health Qual Life Outcomes. 2007. PMID: 17274818 Free PMC article.
-
Adapting the Asthma Life Impact Scale (ALIS) for use in Southern European (Italian) and Eastern European (Russian) cultures.J Med Econ. 2011;14(6):729-38. doi: 10.3111/13696998.2011.615356. Epub 2011 Sep 8. J Med Econ. 2011. PMID: 21899487
-
The development of patient-reported outcome indices for multiple sclerosis (PRIMUS).Mult Scler. 2009 Sep;15(9):1092-102. doi: 10.1177/1352458509106513. Epub 2009 Jun 25. Mult Scler. 2009. PMID: 19556315
-
German translation, cultural adaptation and validation of the unidimensional self-efficacy scale for multiple sclerosis.BMC Neurol. 2021 Apr 17;21(1):163. doi: 10.1186/s12883-021-02183-y. BMC Neurol. 2021. PMID: 33865337 Free PMC article.
Cited by
-
Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study.Mult Scler J Exp Transl Clin. 2020 Sep 13;6(3):2055217320957358. doi: 10.1177/2055217320957358. eCollection 2020 Jul-Sep. Mult Scler J Exp Transl Clin. 2020. PMID: 32974041 Free PMC article.
-
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.Med Devices (Auckl). 2013 Nov 15;6:175-84. doi: 10.2147/MDER.S52590. eCollection 2013. Med Devices (Auckl). 2013. PMID: 24255602 Free PMC article.
-
Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.Mult Scler J Exp Transl Clin. 2016 Oct 9;2:2055217316673235. doi: 10.1177/2055217316673235. eCollection 2016 Jan-Dec. Mult Scler J Exp Transl Clin. 2016. PMID: 28607741 Free PMC article.
-
Validation of a new quality of life scale related to multiple sclerosis and relapses.Qual Life Res. 2013 Oct;22(8):1943-54. doi: 10.1007/s11136-012-0334-0. Epub 2012 Dec 18. Qual Life Res. 2013. PMID: 23247892
-
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).BMC Neurol. 2016 Jul 19;16:109. doi: 10.1186/s12883-016-0629-9. BMC Neurol. 2016. PMID: 27430352 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical